BioMarin licenses Repligen's discontinued HDAC inhibitors
This article was originally published in Scrip
Executive Summary
Repligen licensed its preclinical histone deacetylase (HDAC) inhibitors to BioMarin Pharmaceutical for $2m upfront in a transaction that could reinvigorate a program that was discontinued so that Repligen could focus on its bioprocessing business.